LXT-101

BACKGROUND The thermo-sensitive in situ gels based on copolymers are attractive as an injectable drug delivery carriers for… (More)

In this study, sustained-release of GnRH antagonist peptide LXT-101 was realized through oil formulation, and their releasing… (More)

OBJECTIVES To demonstrate the correlation between the nanostructure formation and the long duration of action in vivo of peptides… (More)

LXT-101, a cationic peptide is a novel antagonist of gonadotropin-releasing hormone (GnRH) for prostate cancer treatment. However… (More)

OBJECTIVES Multivesicular liposomes (MVLs) are often used as an appropriate carrier for delivering peptides due to high drug… (More)

Using a simple method to determine the interaction between peptide and lipid bilayer and then deciding how to modify formulation… (More)

This paper developed a sensitive and specific liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/MS) method… (More)

LXT-101 is a newly developed GnRH (gonadotropin-releasing hormone) analogue. In this study, the in vivo pharmacological profile… (More)

A sustained release poly(DL-lactide-co-glycolide) (PLGA) microsphere delivery system to treat prostate cancer for a luteinizing… (More)